Syntec Optics (Nasdaq: OPTX) Launches Production of New Disposable Optics for Characterization of Biomolecules and Nanoparticles
Syntec Optics (Nasdaq: OPTX) has launched production of new disposable optics for characterizing biomolecules and nanoparticles used in direct light scattering instruments. These optics enable fast measurements for low-volume requirements of proteins, viruses, and gene therapy vectors. Syntec's expertise in intricate disposable optics for diagnostics, surgical instruments, and digital health imaging will now expand to dynamic light-scattering disposable optics.
The company aims to provide next-generation disposable optics for instruments measuring size, mass, stability, and temperature-related characteristics of biomolecules and nanoparticles. This move positions Syntec to tap into the photonics-enabled biomedical marketplace, which SPIE assessed at $201 billion in total revenues for 2021.
Syntec Optics (Nasdaq: OPTX) ha avviato la produzione di nuove ottiche monouso per la caratterizzazione di biomolecole e nanoparticelle utilizzate negli strumenti di diffusione della luce diretta. Queste ottiche consentono misurazioni rapide per requisiti a basso volume di proteine, virus e vettori per la terapia genica. L'esperienza di Syntec nelle ottiche monouso intricate per diagnostica, strumenti chirurgici e imaging della salute digitale si espanderà ora alle ottiche monouso per diffusione della luce dinamica.
L'azienda mira a fornire ottiche monouso di nuova generazione per strumenti che misurano dimensioni, massa, stabilità e caratteristiche legate alla temperatura di biomolecole e nanoparticelle. Questa mossa posiziona Syntec per entrare nel mercato biomedicale abilitato dalla fotonica, che SPIE ha valutato a 201 miliardi di dollari di entrate totali per il 2021.
Syntec Optics (Nasdaq: OPTX) ha lanzado la producción de nuevas ópticas desechables para caracterizar biomoléculas y nanopartículas utilizadas en instrumentos de dispersión de luz directa. Estas ópticas permiten mediciones rápidas para requisitos de bajo volumen de proteínas, virus y vectores de terapia génica. La experiencia de Syntec en ópticas desechables complejas para diagnósticos, instrumentos quirúrgicos e imagenología de salud digital ahora se expandirá a ópticas desechables para dispersión de luz dinámica.
La empresa tiene como objetivo proporcionar ópticas desechables de próxima generación para instrumentos que miden tamaño, masa, estabilidad y características relacionadas con la temperatura de biomoléculas y nanopartículas. Este movimiento posiciona a Syntec para aprovechar el mercado biomédico habilitado por la fotónica, que SPIE evaluó en 201 mil millones de dólares en ingresos totales para 2021.
신텍 옵틱스(Nasdaq: OPTX)는 직접 빛 산란 기기에서 사용되는 바이오 분자 및 나노 입자를 특성화하기 위한 새로운 일회용 옵틱스의 생산을 시작했습니다. 이러한 옵틱스는 단백질, 바이러스 및 유전자 치료 벡터의 저용량 요구 사항에 대한 빠른 측정을 가능하게 합니다. 진단, 외과 기구 및 디지털 건강 이미징을 위한 복잡한 일회용 옵틱스에 대한 신텍의 전문성이 이제 동적 빛 산란 일회용 옵틱스로 확장됩니다.
회사는 바이오 분자와 나노 입자의 크기, 질량, 안정성 및 온도 관련 특성을 측정하는 기기를 위한 차세대 일회용 옵틱스를 제공하는 것을 목표로 하고 있습니다. 이 조치는 신텍이 2021년 SPIE가 총 수익 2,010억 달러로 평가한 광학 기술이 지원하는 생물 의학 시장에 진출할 수 있는 위치를 마련합니다.
Syntec Optics (Nasdaq: OPTX) a lancé la production de nouvelles optiques jetables pour la caractérisation des biomolécules et des nanoparticules utilisées dans des instruments de diffusion de lumière directe. Ces optiques permettent des mesures rapides pour des exigences de faible volume de protéines, de virus et de vecteurs de thérapie génique. L'expertise de Syntec dans les optiques jetables complexes pour le diagnostic, les instruments chirurgicaux et l'imagerie de santé numérique va maintenant s'étendre aux optiques jetables pour la diffusion de lumière dynamique.
La société vise à fournir des optiques jetables de nouvelle génération pour les instruments mesurant la taille, la masse, la stabilité et les caractéristiques liées à la température des biomolécules et des nanoparticules. Ce mouvement positionne Syntec pour pénétrer le marché biomédical permis par la photonique, que SPIE a évalué à 201 milliards de dollars de revenus totaux pour 2021.
Syntec Optics (Nasdaq: OPTX) hat die Produktion neuer Einwegoptiken zur Charakterisierung von Biomolekülen und Nanopartikeln gestartet, die in Instrumenten zur direkten Lichtstreuung verwendet werden. Diese Optiken ermöglichen schnelle Messungen für Anforderungen an geringes Volumen von Proteinen, Viren und Vektoren für Gentherapien. Das Fachwissen von Syntec in komplexen Einwegoptiken für Diagnosen, chirurgische Instrumente und digitale Gesundheitsbildgebung wird nun auf dynamische Lichtstreuungs-Einwegoptiken ausgeweitet.
Das Unternehmen zielt darauf ab, Einwegoptiken der nächsten Generation für Instrumente anzubieten, die Größe, Masse, Stabilität und temperaturbezogene Eigenschaften von Biomolekülen und Nanopartikeln messen. Dieser Schritt positioniert Syntec, um in den photonikgestützten biomedizinischen Markt vorzudringen, der von SPIE für 2021 mit 201 Milliarden Dollar Gesamtumsatz bewertet wurde.
- Launch of new disposable optics production for biomolecule and nanoparticle characterization
- Expansion into dynamic light-scattering disposable optics market
- Potential to tap into the $201 billion photonics-enabled biomedical marketplace
- None.
Insights
Syntec Optics' launch of disposable optics for biomolecule and nanoparticle characterization marks a significant advancement in the field of biopharma research. This development could potentially accelerate drug discovery and development processes, particularly in areas like protein therapeutics and gene therapy.
The key advantages of these new optics include:
- Enabling fast measurements for low-volume samples, which is important in early-stage research where sample quantities are often
- Facilitating the characterization of a wide range of biomolecules, including proteins, viruses and gene therapy vectors.
- Providing precise fluid flow ports, which are essential for accurate and reliable measurements.
From an investor's perspective, this product launch positions Syntec Optics to tap into the growing
However, it's important to note that the success of this product will depend on factors such as adoption rates by research institutions and biopharma companies, competitive pricing and the actual performance of the optics in real-world applications. Investors should monitor these aspects closely in the coming quarters to gauge the impact on Syntec's financials.
Syntec Optics' entry into the biomolecule and nanoparticle characterization optics market is a strategic move that could significantly impact its business trajectory. Here's why:
- Market Opportunity: The
$201 billion photonics-enabled biomedical marketplace (as of 2021) represents a substantial opportunity for growth. Even capturing a small fraction of this market could lead to significant revenue increases for Syntec. - Diversification: By expanding into dynamic light-scattering disposable optics, Syntec is diversifying its product portfolio, potentially reducing reliance on any single market segment.
- Competitive Advantage: Syntec's existing expertise in intricate disposable optics for diagnostics and surgical instruments could provide a competitive edge in this new market.
However, investors should consider the following factors:
- Market Adoption: The rate at which biopharma companies and research institutions adopt these new optics will be important for Syntec's success in this venture.
- Competition: The biomedical optics market is likely competitive and Syntec will need to differentiate its offerings to gain market share.
- R&D Costs: Developing and refining these new optics may require significant ongoing investment in research and development.
While the launch of this new product line is promising, investors should look for concrete sales figures and market penetration data in future financial reports to assess its true impact on Syntec's bottom line.
Plans to ramp new product sales
ROCHESTER, NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Syntec Optics, a leading provider of mission-critical optics for scientific and technical instruments and equipment OEMs in diverse defense, biomedical, communications, and consumer end-markets, announced today that it has launched the production of biomolecules and nanoparticles characterization optics used in direct light scattering instruments for biopharma technologists. Syntec's new disposable optics enable fast measurements for low-volume requirements of proteins, viruses, gene therapy vectors, and more.
Disposable optics require precise ports for the fluid flow of biomolecules and nanoparticles. Syntec Optics has many years of expertise delivering such intricate disposable optics for diagnostics, surgical instruments, and digital health imaging. Syntec will now expand its capability to provide dynamic light-scattering disposable optics.
“We are excited to develop and provide the next-generation disposable optics to enable instruments that can measure the size, mass, stability, and temperature-related characteristics of biomolecules and nanoparticles,” said the Sales Director at Syntec Optics.
SPIE assessed the 2021 photonics-enabled biomedical marketplace as
About Syntec Optics
Syntec Optics Holdings, Inc. (Nasdaq: OPTX), headquartered in Rochester, NY, is one of the largest custom and diverse end-market optics and photonics manufacturers in the United States. Operating for over two decades, Syntec Optics runs a state-of-the-art facility with extensive core capabilities of various optics manufacturing processes, both horizontally and vertically integrated, to provide a competitive advantage for mission-critical OEMs. Syntec Optics recently launched new products, including Low Earth Orbit (LEO) satellite optics, lightweight night vision goggle optics, biomedical equipment optics, and precision microlens arrays. To learn more, visit www.syntecoptics.com.
Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended, including certain financial forecasts and projections. All statements other than statements of historical fact contained in this press release, including statements as to the transactions contemplated by the business combination and related agreements, future results of operations and financial position, revenue and other metrics, planned products and services, business strategy and plans, objectives of management for future operations of Syntec Optics, market size, and growth opportunities, competitive position and technological and market trends, are forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “plan,” “targets,” “projects,” “could,” “would,” “continue,” “forecast” or the negatives of these terms or variations of them or similar expressions. All forward-looking statements are subject to risks, uncertainties, and other factors (some of which are beyond the control of Syntec Optics), which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. All forward-looking statements are based upon estimates, forecasts and assumptions that, while considered reasonable by Syntec Optics and its management, as the case may be, are inherently uncertain and many factors may cause the actual results to differ materially from current expectations which include, but are not limited to: 1) risk outlined in any prior SEC filings; 2) ability of Syntec Optics to successfully increase market penetration into its target markets; 3) the addressable markets that Syntec Optics intends to target do not grow as expected; 4) the loss of any key executives; 5) the loss of any relationships with key suppliers including suppliers abroad; 6) the loss of any relationships with key customers; 7) the inability to protect Syntec Optics’ patents and other intellectual property; 8) the failure to successfully execute manufacturing of announced products in a timely manner or at all, or to scale to mass production; 9) costs related to any further business combination; 10) changes in applicable laws or regulations; 11) the possibility that Syntec Optics may be adversely affected by other economic, business and/or competitive factors; 12) Syntec Optics’ estimates of its growth and projected financial results for the future and meeting or satisfying the underlying assumptions with respect thereto; 13) the impact of any pandemic, including any mutations or variants thereof and the Russian/Ukrainian or Israeli conflict, and any resulting effect on business and financial conditions; 14) inability to complete any investments or borrowings in connection with any organic or inorganic growth; 15) the potential for events or circumstances that result in Syntec Optics’ failure to timely achieve the anticipated benefits of Syntec Optics’ customer arrangements; and 16) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in prior SEC filings including registration statement on Form S-4 filed with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Syntec Optics does not give any assurance that Syntec Optics will achieve its expected results. Syntec Optics does not undertake any duty to update these forward-looking statements except as otherwise required by law.
For further information, please contact:
Sara Hart
Investor Relations
InvestorRelations@syntecoptics.com
SOURCE: Syntec Optics Holdings, Inc. (Nasdaq: OPTX)
FAQ
What new product has Syntec Optics (OPTX) launched production for?
What applications will Syntec Optics' (OPTX) new disposable optics serve?
How large is the photonics-enabled biomedical marketplace that Syntec Optics (OPTX) is targeting?
What specific capabilities will Syntec Optics' (OPTX) new disposable optics provide?
